|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||84.88 - 84.98|
|52 Week Range||26.93 - 84.98|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.
Two of the industry’s leading gene-editing experts have unveiled their next venture: a gene-silencing startup called Triplet Therapeutics.
Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating The Medicines Company (the "Company") (Nasdaq: MDCO) relating to the sale of the Company to Novartis AG. Under the terms of the transaction, shareholders of the Company will receive $85.00 in cash for each share of the Company common stock owned.
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]
Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction ...
The stock market powered higher this week amid M&A; deals like Schwab-TD Ameritrade. Disney, Best Buy and Alibaba were leaders.
Arrowhead Pharmaceuticals grabbed an upgrade Friday as ARWR stock has rocketed 159% since October on enthusiasm for the biotech company's RNAi platform. ARWR stock is 98% above a buy point.
Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of The Medicines Co. ("MDCO" or the "Company") (NASDAQ: MDCO) in connection with the proposed acquisition of the Company by Swiss pharmaceutical company Novartis International A.G. Under the terms of the acquisition agreement, MDCO shareholders will receive $85.00 for each share they own.
Major benchmarks closed at record highs on Monday, thanks to newfound investor optimism around developments in the U.S.-China trade talks and possible completion of the phase one trade agreement before the year runs out.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
Moody's Investors Service has today affirmed the A1 long-term ratings of Swiss multinational pharmaceutical maker Novartis AG (Novartis) and its guaranteed subsidiaries. The affirmation follows the company's announcement on 24 November of plans to acquire The Medicines Company, which is developing Inclisiran - a potential cholesterol lowering drug, for approximately $9.7 billion. "Acquiring The Medicines Company will strengthen Novartis' cardiovascular franchise, however, it comes at a high price," says Knut Slatten, a Moody's Vice President and lead analyst for Novartis.
Novartis, a Swiss drug maker, is acquiring The Medicines Co in a $9.7B dollar deal. The acquisition will place Novartis as a direct challenger to Amgen and Sanofi. Yahoo Finance’s Akiko Fujita and Anjalee Khemlani discuss on The Ticker.
Rowley Law PLLC is investigating potential securities law violations by The Medicines Company (NASDAQ: MDCO) and its board of directors concerning the proposed acquisition of the company by Novartis AG (NYSE: NVS). Stockholders will receive $85.00 for each share of The Medicines Company stock that they hold. The transaction is valued at approximately $9.7 billion and is expected to close in the first quarter of 2020.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, has launched an investigation into whether the board members of The Medicines Company (NASDAQ: MDCO) breached their fiduciary duties or violated the federal securities laws in connection with the company's proposed sale to Novartis AG.
Shares of RNA interference biotech companies surged Monday after Novartis announced its $9.7 billion takeover of The Medicines Company, adding a promising cholesterol drug to its wheelhouse.